Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | MC3R | P41968 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565773 | 0.98 | ADORA3 (0.58) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL11422057 | 0.84 | ADORA3 (0.62) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL5062627 | 0.83 | KDM4E (0.61) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL11205929 | 0.83 | KDM4E (0.59) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL11473900 | 0.78 | TSHR (0.50) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL11205932 | 0.77 | GAA (0.59) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL14921391 | 0.77 | NPC1 (0.51) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL11568341 | 0.76 | TSHR (0.56) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL10756114 | 0.76 | SMYD3 (0.52) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazine Carboxylic Acid Hydrazide SCHEMBL107341 | 0.76 | ADORA3 (0.61) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196396-B1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS WITH TWO COVALENTLY LINKED ACTIVE PRINCIPLES (SODIUM CHANNNEL BLOCKER/P2Y2 RECEPTOR AGONIST) FOR THE TREATMENT OF MUCOSAL SURFACES | UNIV NORTH CAROLINA (US) | 2008-03-26 | — | — | EP | claimed |
| EP-1143896-B1 | METHODS OF HYDRATING THE NASAL MUCOSAL SURFACE | UNIV NORTH CAROLINA (US) | 2006-12-13 | — | — | EP | claimed |
| US-7056524-B2 | Methods of hydrating mucosal surfaces | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-06-06 | — | — | US | claimed |
| EP-1143896-A4 | METHODS OF HYDRATING MUCOSAL SURFACES | UNIV NORTH CAROLINA (US) | 2004-11-24 | — | — | EP | claimed |
| JP-2004513870-A | — | — | 2004-05-13 | — | — | JP | claimed |
| US-6613345-B2 | Compounds of the general formula P1-L-P2; wherein \"P1\" is a pyrazinoylguanidine sodium channel blocker, \"L\" is a linking group, and \"P2\" is either (i) a pyrazinoylguanidine sodium channel blocker or (ii) a P2Y2 receptor agonist, are disclosed | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-09-02 | — | — | US | claimed |
| US-6607741-B2 | For hydration of mucusoal surfaces of airways and gastrointestinal system; treatment of cystic fibrosis, primary ciliary dyskinesia, bronchitis, chronic obstructive airway disease, and pneumonia | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-08-19 | — | — | US | claimed |
| US-20020165239-A1 | Conjugates of sodium channel blockers and methods of using the same | BOUCHER RICHARD C (US) | 2002-11-07 | — | — | US | claimed |
| US-6475509-B1 | Covalent conjugates of sodium channel blockers and active compounds | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-11-05 | — | — | US | claimed |
| US-20020158255-A1 | Conjugates of sodium channel blockers and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-31 | — | — | US | claimed |
| EP-1196396-A1 | CONJUGATES OF SODIUM CHANNEL BLOCKERS AND METHODS OF USING THE SAME | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-04-17 | — | — | EP | claimed |
| US-20010034349-A1 | Methods of hydrating mucosal surfaces | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2001-10-25 | — | — | US | claimed |
| EP-1143896-A1 | METHODS OF HYDRATING MUCOSAL SURFACES | The University of North Carolina at Chapel Hill (US) | 2001-10-17 | — | — | EP | claimed |
| US-6264975-B1 | TOPICAL APPLYING SODIUM CHANNEL BLOCKER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-07-24 | — | — | US | claimed |
| WO-2001005773-A1 | CONJUGATES OF SODIUM CHANNEL BLOCKERS AND METHODS OF USING THE SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000023023-A1 | METHODS OF HYDRATING MUCOSAL SURFACES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-04-27 | — | — | WO | claimed |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | PARION SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210024471-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | PARION SCIENCES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2000023023-A1 | METHODS OF HYDRATING MUCOSAL SURFACES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023023-A1 | METHODS OF HYDRATING MUCOSAL SURFACES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034349-A1 | Methods of hydrating mucosal surfaces | P2RY2, P2RY1, TRPV1 | ADORA3 222/4885TSHR 2140/4885MC4R 1283/4885 |
| US-20210024471-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | CFTR, ELANE, IL5 | ADORA3 664/4885TSHR 3724/4885MC4R 3494/4885 |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | CFTR, ELANE, IL5 | ADORA3 664/4885TSHR 3724/4885MC4R 3494/4885 |
| US-20020165239-A1 | Conjugates of sodium channel blockers and methods of using the same | SCNN1B, P2RY2, P2RY1 | ADORA3 289/4885TSHR 2142/4885MC4R 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.